Across TCGA pan-cancer cohorts, ASB13 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASB13 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ASB13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ASB13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, BLCA, and SKCM are the cancer types where ASB13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
BLCA	OS	Median	III,IV	0.141	0.655	.002	27	view →
SKCM	DFS	Median	III,IV	0.029	0.613	<.001	14	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.035	8	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ASB13 tumor-vs-normal RNA expression · all ASB13 data types